Floatz logo

4sc-201

Hepatocellular Carcinoma

Yakult Honsha Co., LTDPhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

521 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
Carboplatin
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

4sc-201 is also rated in:

mycosis fungoidesDormant
B
Indicative ·
61 / 100
View asset →
Sezary syndromeDormant
B
Indicative ·
61 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →